News Releases

Date Title and Summary Additional Formats
Toggle Summary AVI BioPharma Announces 2006 Fourth Quarter and Year End Financial Results Conference Call
PORTLAND, Ore.--(BUSINESS WIRE)--March 8, 2007--AVI BioPharma Inc. (Nasdaq: AVII) today announced that the company will hold a conference call to discuss its 2006 fourth quarter and year end financial results on Thursday, March 15, 2007, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time).
View HTML
Toggle Summary AVI BioPharma Presents Novel HIV Drug Candidate Results
Cell-Culture Research Targets HIV-1 Vif and Tar Stem Loop PORTLAND, Ore.--(BUSINESS WIRE)--March 1, 2007--AVI BioPharma, Inc. (Nasdaq:AVII), presented research results titled "Morpholino Antisense Oligomers that Target the Lentiviral Vif Gene and Tar Stem Loop are Novel Antiretroviral Drug
View HTML
Toggle Summary AVI BioPharma and Eleos Announce Cross-License Agreement for p53 Therapeutics
PORTLAND, Ore. & OMAHA, Neb.--(BUSINESS WIRE)--Jan. 9, 2007--AVI BioPharma, Inc. (Nasdaq:AVII), and Eleos Inc. announced today a cross-license agreement for the development of antisense drugs targeting p53, a well-studied human protein that controls cellular response to genetic damage.
View HTML
Toggle Summary AVI BioPharma and Ercole Biotech Announce Cross-License and Drug Discovery Collaboration for Alternative Splicing Therapeutics
PORTLAND, Ore. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Dec. 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), and Ercole Biotech, Inc., announced today a cross-license and collaboration agreement to identify and develop drugs that direct the splicing of messenger RNA (mRNA) to treat a variety
View HTML
Toggle Summary AVI BioPharma Announces Clinical Development Initiative for Muscular Dystrophy
Publication of Preclinical Studies Demonstrate Efficacy in Disease Models PORTLAND, Ore.--(BUSINESS WIRE)--Dec. 7, 2006--AVI BioPharma, Inc. (Nasdaq: AVII) today announced the initiation of a clinical program for the treatment of Duchenne Muscular Dystrophy (DMD) using its ESPRIT (Exon Skipping
View HTML
Toggle Summary AVI BioPharma Awarded $28 Million Biodefense Research Contract by Department of Defense/DTRA
PORTLAND, Ore., Dec 04, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (Nasdaq: AVII), has executed a two-year $28 million research contract with the Defense Threat Reduction Agency (DTRA) of Fort Belvoir, Va., an agency of the United States Department of Defense (DoD).
View HTML
Toggle Summary AVI Biopharma 2006 Third Quarter Financial Results Conference Call Transcript
Moderator: Denis Burger November 15, 2006 8:00 a.m. Pacific Time Operator: Ladies and gentlemen, welcome to the AVI BioPharma 2006 Third Quarter Financial Results conference call. At this time all participants are in a listen–only mode. Following management’s prepared remarks we will hold a Q&A
View HTML
Toggle Summary AVI BioPharma Announces Positive Clinical Trial Results Delivering NEUGENE Antisense Drugs to the Central Nervous System
Antisense drugs targeting hepatitis C virus, West Nile virus, and the oncogene c-myc found in the CSF after systemic administration to humans PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 10, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), today announced human clinical trial results showing that three distinct
View HTML
Toggle Summary AVI BioPharma Reports Third Quarter Financial Results
PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 8, 2006--AVI BioPharma, Inc. (Nasdaq:AVII) today reported financial results for the three and nine months ended September 30, 2006. The net loss for the third quarter of 2006 was $6.8 million, or $0.13 per share, compared with a net loss for the third quarter
View HTML
Toggle Summary AVI BioPharma to Present Strategic Overview at Two Investor Conferences
Presentations to Take Place at Rodman & Renshaw 8th Annual Global Healthcare Conference and Paulson Investment's 29th Annual Westergaard SmallCap Conference PORTLAND, Ore.--(BUSINESS WIRE)--Nov. 6, 2006--AVI BioPharma, Inc. (Nasdaq:AVII), President and COO Alan P.
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.